Posted On: 11/15/2016 10:39:20 AM
Post# of 72443
Otezla only shows moderate efficacy by week 16. about 28% show improvement. but Celgene will get 2 billion bucks for this next year.
Vitae has a psoriasis drug that moderates Interleukin-17. They did a deal for 640 million bucks. Dr. Reddy's did deal for Xenocort for half a billion. Another big deal for a monoclonal antibody. (editorial comment: monoclonal antibodies often have bad side effects.)
Dr. B's point: there's a big market out there with lots of deals.
Vitae has a psoriasis drug that moderates Interleukin-17. They did a deal for 640 million bucks. Dr. Reddy's did deal for Xenocort for half a billion. Another big deal for a monoclonal antibody. (editorial comment: monoclonal antibodies often have bad side effects.)
Dr. B's point: there's a big market out there with lots of deals.
(3)
(0)Scroll down for more posts ▼
